Introduction
============

Pulmonary hypertension (PH) is a common complication of a chronic lung disease (CLD) and is associated with increased mortality.[@b1-copd-12-1741],[@b2-copd-12-1741] PH often progresses to right heart failure (RHF), with initial compensatory right ventricle (RV) hypertrophy becoming overwhelmed by increasing pulmonary artery pressure (PAP). According to the updated conference consensus,[@b2-copd-12-1741],[@b3-copd-12-1741] CLD is classified into three groups: without PH (mean PAP \[mPAP\] \<25 mmHg), with PH (mPAP ≥25 mmHg), and with severe PH (mPAP ≥35 mmHg or 25 mmHg \< mPAP \<35 mmHg with cardiac index \<2.0 L/min/m^2^ or pulmonary vascular resistance \[PVR\] \>6 Wood units). However, the severe PH group includes only a minority of patients with CLD who are suspected of having extensive general vascular remodeling accompanying the parenchymal disease that develops independently from pulmonary functional impairment and who have a poor prognosis. The detection of severe PH is important because it can provide the prognostic information to warrant more aggressive respiratory support and interventional cardiovascular procedures.

Right heart catheterization (RHC) is the gold standard for the diagnosis of severe PH because this method provides the hemodynamic information that defines this disease. Nevertheless, RHC is not routinely and repeatedly performed at initial diagnosis of PH and follow-up, especially in the People's Republic of China, where performance of RHC is limited by its invasiveness and high expenses. As a PH-screening tool, systolic PAP (PASP) can be estimated by measuring the peak tricuspid regurgitation velocity (TRV) on echocardiography, which continues to be recommended for early screening and as an assessment tool in patients with pulmonary arterial hypertension (PAH). However, in spite of its widespread use, the accuracy and reproducibility of echocardiography in predicting PASP have recently been questioned.[@b4-copd-12-1741]--[@b9-copd-12-1741]

The recently updated European Society of Cardiology (ESC) and European Respiratory Society guidelines on PH recommend testing for additional PH signs by assessing pulmonary artery diameter (PAd) and RV enlargement in addition to PASP.[@b10-copd-12-1741] Whether a novel comprehensive echocardiography scoring index (ESI) derived from additional PH signs and PASP could improve the value of echocardiography for predicting severe PH was unknown.

Since patients with CLD accompanied by severe PH have a much poorer prognosis, this population attracts clinicians' attention, particularly because early and adequate treatment is needed to improve patient prognosis. Furthermore, it remains undetermined whether the assessment of a comprehensive ESI is beneficial for predicting severe PH. In the current study, we aimed to analyze the value of a comprehensive ESI for predicting severe PH in patients with CLD.

Materials and methods
=====================

Ethics
------

This study was conducted in accordance with the amended Declaration of Helsinki. The Local Institutional Ethics Committee of Shanghai Pulmonary Hospital approved the protocol (K08-015C), and written informed consent was obtained from all the patients in the validation cohort.

Study design
------------

The retrospective derivation cohort and the prospective validation cohort were obtained from the Cardio-Pulmonary Circulation Center of Shanghai Pulmonary Hospital, which is the largest referral center for the diagnosis and treatment of PH in Shanghai, People's Republic of China.[@b11-copd-12-1741] For the derivation cohort, all consecutive patients with CLD hospitalized between January 2012 and December 2014 who were suspected of PH were included for model derivation. The validation cohort included a similar population recruited between January 2015 and July 2015 for model verification.

Inclusion and exclusion criteria
--------------------------------

The patient inclusion criteria were as follows: 1) suspected PH associated with CLD;[@b12-copd-12-1741] 2) diagnosis of CLD confirmed by experienced specialists according to the appropriate guidelines;[@b13-copd-12-1741],[@b14-copd-12-1741] and 3) performance of RHC and Doppler echocardiography at a clinically stable stage during optimal medical therapy.

Patients were excluded for the following reasons: 1) diagnosis of other types of PH as per the NICE criteria;[@b12-copd-12-1741] 2) lack of RHC or echocardiography at a clinically stable stage; or 3) comorbidity of pulmonary embolism, severe left heart disease, and so on.

Procedures
----------

A comprehensive set of quantitative echocardiography parameters was measured at rest (Vivid7 Dimension; GE Vingmed Ultrasound AS, Horten, Norway). The protocol and reference limits were in accordance with the current guidelines.[@b15-copd-12-1741] Right ventricular end-diastolic transverse dimension (RVEDTD), right ventricular end-diastolic longitudinal dimension (RVEDLD), right atrial transverse dimension (RATD), right atrial longitudinal dimension (RALD), and end-systolic-stage eccentricity index (ENDSEI) were measured to indicate the presence or absence of right heart enlargement.[@b15-copd-12-1741] PASP was measured by TRV with right atrium pressure (RAP) estimated by inferior cava diameter and inspiratory collapse.[@b15-copd-12-1741] The PAd was also measured.[@b15-copd-12-1741] RV function was assessed by measuring the tricuspid annular plane systolic excursion (TAPSE).[@b15-copd-12-1741] Left ventricular ejection fraction was measured using M-mode in the parasternal long-axis view.

RHC was performed as described previously.[@b16-copd-12-1741] The baseline hemodynamic variables evaluated included mPAP, RAP, pulmonary artery wedge pressure (PAWP), cardiac output (CO), cardiac index, and PVR.

All patients underwent RHC and echocardiography within 7 days at a clinically stable stage. Echocardiography was performed by two cardiologists (RJ and Q-HZ) who were blinded to all patients' medical history and RHC results. Similarly, the doctors who performed RHC were also blinded to the echocardiography results.

Statistical analysis
--------------------

Continuous variables are described as the mean ± SD and median (interquartile range) for normally distributed variables and skewed distributed variables, respectively. Categorical variables are expressed as percentages. Pearson correlation coefficients for PASP between RHC and echocardiography (abbreviated as PASP~RHC~ and PASP~ECHO~, respectively) were calculated.

All echocardiography parameters were used to model the probability of having severe PH by means of binary logistic regression.[@b17-copd-12-1741] A stepwise selection procedure was used to find independent predictors of severe PH with p-to-enter of ≤0.10 and p-to-remove of ≥0.15. Variables assigned based on multiples of their rounded β-coefficients from the refitted model were used to define an ESI. All patients were classified into either the normal/PH group or the severe PH group. The receiver-operating characteristic (ROC) method was used to assess the ability of echocardiography variables and ESI to predict severe PH. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated.

To verify the ESI's diagnostic ability, we conducted an internal and prospective validation. Landis and Koch[@b18-copd-12-1741] defined kappa values of 0.00--0.20 as slight, 0.21--0.40 as fair, 0.41--0.60 as moderate, 0.61--0.80 as substantial, and 0.81--1.00 as almost perfect agreement. CIs were calculated with the adjusted percentile bootstrap method (n=10,000 replicates).

In all univariate analyses, *P*≤0.05 was considered statistically significant. All statistical methods were performed using SPSS 21.0 software (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5.04 software (GraphPad Software, Inc., San Diego, CA, USA).

Results
=======

Derivation cohort
-----------------

A total of 369 patients with CLD and suspected PH were admitted to our center between January 2012 and December 2014, of whom 107 underwent echocardiography ≤7 days before RHC (mean 3.3±1.3 days before RHC; [Figure 1](#f1-copd-12-1741){ref-type="fig"}). Fifty-six patients with severe PH and 51 patients with normal/PH with a median age of 62.0 (54.0, 67.5) years and consisting of 63.8% men were included. A small proportion of patients had significant comorbidities, such as systemic hypertension (19.0%), diabetes mellitus (3.9%), coronary heart disease (4.8%), arrhythmia (9.5%), and hyperlipidemia (2.9%) ([Table 1](#t1-copd-12-1741){ref-type="table"}). There were no significant differences in demographic characteristics, diagnostic classification, World Health Organization function class (WHO-FC), comorbidities, or pulmonary function test results between the groups ([Table 1](#t1-copd-12-1741){ref-type="table"}).

The PASP~ECHO~ was measured at a clinically stable stage in 86.9% of all patients, which included 80.4% of the normal/PH group and 92.8% of the severe PH group. There was a moderately strong correlation between PASP~ECHO~ and both PASP~RHC~ and mPAP~RHC~ (*r*=0.665 and *r*=0.650, both *P*\<0.001). Compared with the normal/PH group, the severe PH group showed significant abnormalities in the variables of echocardiography and RHC (all *P*\<0.001) ([Table 1](#t1-copd-12-1741){ref-type="table"}).

Multivariate analyses were performed to construct the ESI. Age, RATD, RALD, RVEDLD, and ENDSEI were excluded due to nonsignificant results by multivariate analysis, despite achieving statistical significance by univariate analysis. Stepwise logistic regression analysis revealed four variables that were independently significant: RVEDTD, PASP, PAd, and TAPSE. The formula for ESI was derived from the β-coefficients in the final model ([Table 2](#t2-copd-12-1741){ref-type="table"}): ESI = ESI~RVEDTD~ + ESI~PASP~ + ESI~PAd~ − ESI~TAPSE~.

Based on ROC analysis, PASP ≥61 mmHg displayed 80.4% sensitivity and 84.3% specificity with an area under ROC curve (AUC) of 0.823 (95% CI: 0.797--0.942, *P*\<0.0001). The other parameters, except for RVEDTD, did not seem to have good sensitivity and specificity for predicting severe PH ([Table 3](#t3-copd-12-1741){ref-type="table"}). Compared with PASP~ECHO~, the ESI resulted in a net improvement in model performance, with a change in the *c*-statistic from 0.823 to 0.937 (95% CI: 0.890--0.984, *P*\<0.001) and an integrated discrimination improvement of 11.3% (95% CI: 4.5%--18.2%, *P*=0.001) ([Figure 2](#f2-copd-12-1741){ref-type="fig"}).

Since severe PH should capture clinicians' attention due to its poor prognosis, to minimize the chance of overlooking a case of severe PH, we examined several alternate cutoff values of the ESI and determined the cutoff value that maximized sensitivity with the least compromise in specificity ([Table S1](#SD1-copd-12-1741){ref-type="supplementary-material"}). Therefore, we chose 1.0 as the optimal cutoff value for the ESI. With ESI ≥1.0 as the definition of a model-predicted case of severe PH, the sensitivity, specificity, PPV, and NPV were 91.1%, 80.4%, 83.6%, and 89.1%, respectively.

[Figure 3](#f3-copd-12-1741){ref-type="fig"} shows representative echocardiography traces from two patients with CLD who were verified as having mild or severe PH on RHC.

Validation cohort
-----------------

A total of 127 patients with CLD and suspected PH between Jan 2015 and Jul 2015 were admitted to our center, of whom 16 adult patients had normal/mild PH and 19 had severe PH. Clinical data are presented in [Tables S2](#SD2-copd-12-1741){ref-type="supplementary-material"} and [S3](#SD3-copd-12-1741){ref-type="supplementary-material"}. A trend towards lower PASP~ECHO~ or PASP~RHC~ and mean RAP was seen in the validation cohort. The ESI was validated in the cohort with 84.2% sensitivity, 81.3% specificity, 84.2% PPV, 81.3% NVP, and 82.9% accuracy. The ESI showed precise and substantial kappa agreement (0.655, 95% CI: 0.370--0.884).

Discussion
==========

We derived and validated a comprehensive ESI by combining additional PH signs and PASP~ECHO~ for predicting severe PH in patients with CLD. ESI ≥1.0 displayed satisfactory sensitivity, specificity, PPV, NPV, and accuracy in predicting severe PH and is recommended to be applied in clinical prac-tice due to its noninvasive nature and cost effectiveness.

Despite availability of targeted PH medication for PAH, no targeted medication is approved at the moment for PH in CLD and use of targeted drugs would be off-label. Compared with patients with CLD in the normal/PH group, patients in the severe PH group exhibited poorer prognosis and higher mortality.[@b10-copd-12-1741],[@b19-copd-12-1741] Therefore, it is important for clinicians to detect severe PH in patients earlier and to initiate adequate treatment in order to improve patient prognosis. RHC is the gold standard for measuring not only mPAP but also PAWP, cardiac index, CO, and PVR. RHC cannot be replaced by echocardiography. Nevertheless, RHC cannot be performed in every hospital, especially in the People's Republic of China. Sometimes, patients are not willing to undergo RHC during follow-up because of its invasiveness and cost. However, as a PH-screening tool, PASP can be estimated by measuring the peak TRV on echocardiography, which continues to be recommended for early screening and assessment in patients with idiopathic PAH, chronic thromboembolism-associated PH, or connective tissue disease-associated PAH.[@b20-copd-12-1741] However, PASP estimation is often inaccurate, especially in patients with CLD, and requires the presence of sufficient tricuspid regurgitation (TR), proper Doppler alignment, and optimal visualization of the regurgitant jet. Moreover, the absence of TR is not sufficient to exclude PH, and the TRV might be underestimated in patients with CLD who have hyperinflation of the lungs and marked respiratory variations in intrathoracic pressure.[@b9-copd-12-1741] Even if a TR is observed, PAP~ECHO~ is often inaccurate and leads to both false-positive and false-negative diagnoses of PH,[@b19-copd-12-1741] not to mention an inability to determine severe PH. Compared with PASP~RHC~, PASP~ECHO~ was found to be inaccurate in 52% of COPD cases, with a tendency to overestimate PAP.[@b9-copd-12-1741] Indeed, 48% of patients were misclassified as having PH by echocardiography alone.[@b9-copd-12-1741],[@b21-copd-12-1741] In addition, some studies have identified a strong relationship between mPAP~ECHO~ and mPAP~RHC~.[@b22-copd-12-1741] However, the diagnostic utility of mPAP~ECHO~ for specific underlying etiologies, such as emphysema, has been questioned.[@b21-copd-12-1741] In other studies,[@b9-copd-12-1741],[@b23-copd-12-1741] PASP~ECHO~ predicted PH in patients with CLD with 76%--85% sensitivity, 17%--38% specificity, 56%--60% PPV, and 44%--60% NPV. Consequently, PASP~ECHO~ and mPAP~ECHO~ have not yet been adopted as stand-alone tools capable of accurately measuring pulmonary hemodynamics.

At present, this ESC guideline suggests grading the probability of PH based on TRV and additional prespecified echocardiographic variables that are suggestive of PH.[@b10-copd-12-1741] Additional signs of PH such as RV dilation, eccentricity index, and PAd[@b24-copd-12-1741] have been reported to discern PAH with high sensitivity. Many years ago, several studies derived and validated equations using additional PH signs to estimate PVR or mPAP as confirmed by RHC in patients with PH.[@b4-copd-12-1741],[@b5-copd-12-1741],[@b23-copd-12-1741] Prior studies have tried but failed to utilize acceleration time in the right ventricular outflow tract (RVOT) to measure PAP or predict PH in patients with CLD.[@b25-copd-12-1741],[@b26-copd-12-1741] Opotowsky et al reported that the RVOT velocity or RVOT velocity time integral has been proposed as a PVR prediction model[@b5-copd-12-1741],[@b8-copd-12-1741] for determining the severity of PH with the exception of PH due to CLD[@b24-copd-12-1741] or for estimating PAP in children with CLD.[@b27-copd-12-1741] However, the above-stated methods were slightly more cumbersome, and we favor simply measured variables to increase clinical utility.

In our research, we derived a novel comprehensive index by combining RVEDTD, PAd, and TAPSE in addition to PASP~ECHO~. This index has several advantages. First, the ESI's sensitivity and specificity are substantially higher than PASP~ECHO~, with an increase in the *c*-statistic from 0.823 to 0.937. Second, the four variables are not cumbersome to measure and are easy to obtain. Third, the ESI is noninvasive, reliable, and easy to integrate into clinical practice, especially during follow-up.

D'Alto et al[@b6-copd-12-1741] reported that echocardiography allows for accurate measurements of pulmonary circulation but with moderate precision by Bland--Altman analysis, which explains why the procedure is valid for population studies but cannot be used for the diagnosis of PH in individual patients. Because our research objective is to make a cutoff value to differentiate "severe PH" from "normal/PH" rather than replace gold criterion by new parameter, Bland--Altman analysis might not be suitable for our research. We calculated accuracy and precision in accordance with categorical variable and kappa, respectively. In our study, there were no significant biases, and the ESI showed 82.9% accuracy in the validation cohort. However, the ESI had a kappa statistic of 0.655, indicating substantial but not high agreement. Our results are consistent with earlier reports and could help clinicians perform preliminary screening of patients with suspected severe PH.

Although the parameter for the discrimination of severe PH is an mPAP of 35 mmHg by RHC, the corresponding PASP~ECHO~ of 61 mmHg derived from the sample seems very high. This is far greater than the calculated PASP of 53 mmHg[@b7-copd-12-1741] or 54 mmHg[@b28-copd-12-1741] for an mPAP of 35 mmHg. This indicates that PASP~ECHO~ was not sufficient for predicting PH in patients with CLD.

As we know, the severity of PH should not be judged by PAP but rather by clinical outcomes such as WHO-FC, hospitalization, RHF, up-titration of medications, transplantation, or mortality. However, our research was a diagnostic study that validated the capacity of a comprehensive echocardiography index for predicting severe PH in patients with CLD. In the future, our research would be strengthened by determining the predictive nature of the formula in clinical outcomes from the validation cohort. A formula that could predict clinical outcomes in this population would be more useful. We will further consider this problem when we have a large patient cohort that can be followed over time and will develop a formula based on those data.

Study limitations
-----------------

This study has several limitations that need to be considered when interpreting the results. First, this was a single-center study, which may have patient selection bias because not all the patients with CLD had undergone RHC. However, patients admitted into our center came from all over People's Republic of China, which may reduce bias. Second, echocardiography and RHC were not conducted simultaneously; therefore, the delay between procedures could be considered a limitation of this study. However, the included patients received similar levels of support and treatment at the times of echocardiography and RHC, and there were no detectable differences in medications or fluid status between the two groups. All patients underwent RHC at a clinically stable stage, manifesting relief of respiratory failure and RHF. The number of days between echocardiography and RHC was also validated as insignificant by logistical regression. Importantly, the strength of the present study is the evaluation of these tests through actual application in clinical practice.

Conclusion
==========

We present a simple clinical tool that helps to predict severe PH in patients with CLD. The integrated ESI combining additional PH signs and PASP~ECHO~ improved the accuracy of predicting severe PH based on echocardiography. If patients with CLD have an ESI \>1.0, they should receive clinicians' attention and should undergo RHC because they may have a high risk of severe PH and pulmonary vascular remodeling. Early diagnosis and treatment are crucial in this patient population.

Supplementary materials
=======================

###### 

Sensitivity, specificity, positive predictive values, and negative predictive values of the diagnostic index

  Cutoff values       Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)
  ------------------- ----------------- ----------------- --------- ---------
  Derivation cohort                                                 
   Cutoff =1.5        87.5              92.2              92.5      87.0
   Cutoff =1.0        91.1              80.4              83.6      89.1
  Validation cohort                                                 
   Cutoff =1.5        64.7              76.9              78.6      62.5
   Cutoff =1.0        81.3              84.2              84.2      81.3

**Abbreviations:** PPV, positive predictive value; NPV, negative predictive value.

###### 

Comparison of characteristics of patients of derivation cohort vs validation cohort

  Variable                                                                   Derivation cohort (n=107)   Validation cohort (n=35)   *P*-value
  -------------------------------------------------------------------------- --------------------------- -------------------------- -----------
  Age (years)                                                                63.0 (54.0, 70.0)           63.0 (56.5, 68.0)          0.998
  Men (%)                                                                    67                          21                         0.458
  BSA (m^2^)                                                                 1.6 (0.2)                   1.6 (0.2)                  0.204
  Diagnosis                                                                                                                         
   COPD                                                                      36 (80.0)                   27 (90.0)                  0.157
   ILD                                                                       4 (8.9)                     3 (10.0)                   0.863
   Bronchiectasia                                                            10 (22.2)                   8 (26.7)                   0.962
   Other pulmonary diseases with mixed restrictive and obstructive pattern                                                          
    CPFE                                                                     1 (2.2)                     1 (3.3)                    0.893
    Lobectomia pulmonalis                                                    4 (8.9)                     0                          0.229
    Chest deformity                                                          1 (2.2)                     1 (6.7)                    0.320
    Emphysema and bullae                                                     2 (4.4)                     4 (13.3)                   0.228
    Lung destruction due to tuberculosis                                     3 (6.7)                     1 (3.3)                    0.286
   Pneumoconiosis                                                            1 (2.2)                     0                          0.452
   Sleep-disordered breathing                                                1 (2.2)                     0                          0.356
   Alveolar hypoventilation disorders                                        2 (4.4)                     0                          0.452
  Comorbidities                                                                                                                     
   Systemic hypertension                                                     20 (19.0)                   7 (23.3)                   0.493
   Diabetes mellitus                                                         4 (3.9)                     2 (6.7)                    0.490
   Coronary heart disease                                                    4 (4.8)                     1 (3.3)                    0.420
   Malignant tumor                                                           1 (1.0)                     1 (3.3)                    0.629
   Arrhythmia                                                                10 (9.5)                    2 (6.7)                    0.460
   Hyperlipidemia                                                            3 (2.9)                     2 (6.7)                    0.320
   Previous cerebral infarction                                              1 (1.0)                     0                          0.596
  Pulmonary function test                                                                                                           
   FEV~1~ % predicted                                                        32.8 (23.7, 60.4)           33.0 (20.0, 44.3)          0.201
   FVC % predicted                                                           53.0 (39.5, 63.3)           56.4 (43.9, 63.0)          0.406
   FEV~1~/FVC % predicted                                                    55.2 (44.5, 69.0)           45.0 (39.7, 67.5)          0.067
   RV % predicted                                                            156.9 (106.3, 217.0)        196.4 (108.1, 304.0)       0.237
   TLC % predicted                                                           100.5 (80.8, 122.1)         107.2 (78.3, 135.4)        0.461
   RV/TLC % predicted                                                        67.2 (53.9, 78.1)           71.1 (51.0, 79.5)          0.681
   DLco % predicted                                                          48.9 (26.9, 64.2)           29.6 (23.5, 53.8)          0.128
   DLco/VA % predicted                                                       50.8 (27.2, 72.6)           35.4 (23.2, 66.8)          0.292

**Note:** Data shown as mean (SD) or median (quartile range).

**Abbreviations:** BSA, body surface area; ILD, interstitial lung disease; CPFE, combined pulmonary fibrosis and emphysema; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; DLco, diffusing capacity for carbon monoxide; VA, alveolar volume.

###### 

Comparison of hemodynamics and echocardiography parameters of patients of derivation cohort vs validation cohort

  Variable                                                                Derivation cohort (n=107)   Validation cohort (n=35)   *P*-value
  ----------------------------------------------------------------------- --------------------------- -------------------------- -----------
  Hemodynamics                                                                                                                   
   mRAP (mmHg)                                                            5.0 (3.0, 8.0)              3.0 (1.0, 5.0)             0.001
   mPAP (mmHg)                                                            36.0 (29.0, 48.0)           35.0 (28.5, 42.0)          0.169
   PAWP (mmHg)                                                            9.2 (3.8)                   8.2 (5.3)                  0.188
   CO (L/min)                                                             5.0 (4.2, 6.1)              5.0 (4.2, 6.5)             0.716
   Cardiac index (L/min/m^2^)                                             3.3 (0.9)                   3.2 (0.8)                  0.820
   PVR (Wood units)                                                       3.6 (3.5, 8.1)              5.0 (3.0, 7.3)             0.484
  Echocardiography parameters                                                                                                    
   Continuous variables                                                                                                          
    LVEF (%)                                                              70.0 (64.0, 77.0)           70.5 (62.0, 77.3)          0.186
    RATD (cm)                                                             4.4 (3.7, 5.3)              4.3 (3.7, 4.6)             0.256
    RALD (cm)                                                             4.8 (4.1, 5.7)              4.6 (4.2, 5.2)             0.274
    RVEDTD (cm)                                                           3.9 (3.3, 4.5)              3.7 (3.5, 4.2)             0.581
    RVEDSD (cm)                                                           6.2 (5.6, 6.8)              6.1 (5.7, 6.9)             0.971
    PASP (mmHg)                                                           60.0 (43.0, 76.0)           51.0 (35.0, 65.0)          0.009
    TAPSE (cm)                                                            1.8 (1.6, 2.0)              1.8 (1.6, 2.2)             0.940
    PAd (cm)                                                              2.6 (2.4, 2.9)              2.8 (2.5, 3.0)             0.103
    ENDSEI                                                                1.1 (1.0, 1.3)              1.1 (1.0, 1.3)             0.338
   Categorical variables                                                                                                         
    RH enlargement[\*](#tfn12-copd-12-1741){ref-type="table-fn"} -- yes   81 (75.7%)                  22 (73.3%)                 0.792
    PA dilation -- yes                                                    48 (44.9%)                  17 (56.7%)                 0.094
    ENDSEI -- yes                                                         60 (56.1%)                  15 (50.0%)                 0.556
    PASP -- yes                                                           93 (86.9%)                  17 (56.7%)                 \<0.001

**Notes:** Data shown as mean (SD), median (25th, 75th percentiles) or n (%).

Include right atrium and right ventricle enlargement.

**Abbreviations:** mRAP, mean right atrium pressure; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; CO, cardiac output; PVR, pulmonary vascular resistance; LVEF, left ventricular ejection fraction; RATD, right atrial transverse dimension; RALD, right atrial longitudinal dimension; RVEDTD, right ventricular end-diastolic transverse dimension; RVEDSD, right ventricular end-diastolic dimension; PASP, pulmonary artery systolic pressure; TAPSE, tricuspid annular plane systolic excursion; PAd, pulmonary arterial diameter; ENDSEI, end-systolic eccentricity index; RH, right heart; PA, pulmonary artery.
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![Flow diagram for the main derivation cohort. Of the 369 patients with CLD and suspected PH who were referred to the Cardio-Pulmonary Circulation Center of Shanghai Pulmonary Hospital within the study period, 107 met the inclusion criteria and were considered in the analysis.\
**Abbreviations:** CLD, chronic lung disease; PH, pulmonary hypertension; RHC, right heart catheterization; DE, Doppler echocardiography.](copd-12-1741Fig1){#f1-copd-12-1741}

![The receiver-operator characteristic curve is shown for PASP alone as determined by echocardiography variables and for ESI in predicting severe PH.\
**Abbreviations:** PASP, pulmonary arterial systolic pressure; ESI, echocardiography scoring index; PH, pulmonary hypertension; AUC, area under the curve; DE, Doppler echocardiography.](copd-12-1741Fig2){#f2-copd-12-1741}

![Representative echocardiographic images of RVEDTD, PASP, PAd, and tricuspid annular plane systolic excursion as well as the score calculation for two patients. Column **A** (top to bottom) shows ↑RVEDTD and ↑PASP (score =−1). Invasive hemodynamics: mPAP =30 mmHg, PAWP =11 mmHg, PVR =6.0 Wood units, and cardiac index =3.1 L/min/m^2^. Column **B** shows ↑RVEDTD, ↑PASP, ↑PAd, and ↓TAPSE (score =4). Invasive hemodynamics: mPAP =39 mmHg, PAWP =11 mmHg, PVR =6.0 Wood units, and cardiac index =3.35 L/min/m^2^.\
**Abbreviations:** RVEDTD, right ventricular end-diastolic transverse dimension; PASP, pulmonary arterial systolic pressure; PAd, pulmonary artery diameter; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; TAPSE, tricuspid annular plane systolic excursion; ESI, echocardiography scoring index.](copd-12-1741Fig3){#f3-copd-12-1741}

###### 

Demographic characteristics, pulmonary function test results, hemodynamics, and echocardiography parameters of patients with normal/PH vs severe PH

  Variable                                                         Normal/PH (n=51)    Severe PH (n=56)    *P*-value
  ---------------------------------------------------------------- ------------------- ------------------- -----------
  Age (years)                                                      64.0 (57.5, 70.5)   61.0 (48.0, 67.8)   0.059
  Men                                                              30 (66.7%)          37 (61.7%)          0.638
  BSA (m^2^)                                                       1.6±0.2             1.6±0.2             0.543
  Diagnosis                                                                                                
   COPD                                                            35 (68.6%)          40 (71.4%)          0.753
   Interstitial lung disease                                       4 (7.8%)            6 (10.7%)           0.612
   Other diseases with mixed restrictive and obstructive pattern                                           
    Combined pulmonary fibrosis and emphysema                      1 (2.0%)            1 (1.8%)            0.947
    Lobectomia pulmonalis                                          3 (5.9%)            1 (1.8%)            0.267
    Chest deformity                                                1 (2.0%)            1 (1.8%)            0.947
    Lung destruction due to tuberculosis                           3 (5.9%)            2 (3.6%)            0.573
    Bronchiectasis                                                 1 (2.0%)            3 (5.4%)            0.357
    Pneumoconiosis                                                 1 (2.0%)            0 (1.7%)            0.295
   Sleep-disordered breathing                                      1 (2.0%)            2 (3.6%)            0.616
   Alveolar hypoventilation disorders                              1 (2.0%)            0                   0.295
  Comorbidities                                                                                            
   Systemic hypertension                                           10 (22.2%)          10 (16.7%)          0.616
   Diabetes mellitus                                               3 (6.7%)            1 (1.7%)            0.311
   Coronary heart disease                                          4 (8.9%)            1 (1.7%)            0.162
   Malignant tumor                                                 0                   1 (1.7%)            0.386
   Arrhythmia                                                      6 (13.3%)           4 (6.7%)            0.320
   Hyperlipidemia                                                  3 (6.7%)            0                   0.076
   Previous cerebral infarction                                    0                   1 (1.7%)            0.386
  Pulmonary function test                                                                                  
   FEV~1~ % predicted                                              48.8±23.3           48.5±21.0           0.309
   FVC % predicted                                                 67.5±25.4           62.0±20.7           0.664
   FEV~1~/FVC % predicted                                          57.7±18.2           61.9±16.1           0.409
   RV % predicted                                                  178.9±62.9          156.3±55.3          0.178
   TLC % predicted                                                 109.5±27.4          101.2±19.6          0.197
   DLco % predicted                                                51.4±27.4           57.6±33.9           0.471
  Hemodynamics                                                                                             
   mRAP (mmHg)                                                     4.0 (2.0, 5.0)      7.0 (4.0, 9.0)      \<0.001
   mPAP (mmHg)                                                     29.0 (24.5, 32.0)   47.0 (41.0, 57.5)   \<0.001
   PAWP (mmHg)                                                     8.1±3.4             9.9±4.3             0.022
   CO (L/min)                                                      5.7 (4.3, 6.6)      4.7 (4.0, 5.7)      0.034
   Cardiac index (L/min/m^2^)                                      3.5±0.8             3.2±1.0             0.192
   PVR (Wood units)                                                3.6 (2.4, 4.8)      7.9 (6.2, 10.2)     \<0.001
  Echocardiography                                                                                         
   LVEF (%)                                                        69.1±7.6            71.3±9.3            0.186
   RATD (cm)                                                       4.0 (3.5, 4.7)      4.8 (3.2, 5.5)      \<0.001
   RALD (cm)                                                       4.5 (3.9, 5.4)      5.2 (4.5, 6.0)      0.005
   RVEDTD (cm)                                                     3.5 (3.1, 3.9)      4.3 (3.8, 5.0)      \<0.001
   RVEDLD (cm)                                                     5.8 (5.5, 6.7)      6.5 (5.8, 7.1)      0.011
   PASP (mmHg)                                                     47.4±11.6           76.0±21.9           \<0.001
   TAPSE (cm)                                                      2.0±0.3             1.7±0.3             \<0.001
   PAd (cm)                                                        2.4 (2.2, 2.7)      2.8 (2.6, 3.2)      \<0.001
   ENDSEI                                                          1.0 (1.0, 1.1)      1.3 (1.1, 1.5)      \<0.001
   PASP -- yes                                                     41 (80.4%)          52 (92.9%)          0.057

**Note:** Data shown as mean ± SD, n (%) or median (quartile range).

**Abbreviations:** PH, pulmonary hypertension; BSA, body surface area; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; DLco, diffusing capacity for carbon monoxide; mRAP, mean right atrium pressure; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; CO, cardiac output; PVR, pulmonary vascular resistance; LVEF, left ventricular ejection fraction; RATD, right atrial transverse dimension; RALD, right atrial longitudinal dimension; RVEDTD, right ventricular end-diastolic transverse dimension; RVEDLD, right ventricular end-diastolic longitudinal dimension; PASP, pulmonary arterial systolic pressure; TAPSE, tricuspid annular plane systolic excursion; PAd, pulmonary artery diameter; ENDSEI, end-systolic-stage eccentricity index.

###### 

Logistic regression analysis of echocardiography parameters associated with severe PH

  Variable[\*](#tfn3-copd-12-1741){ref-type="table-fn"}   Univariate analysis      β-coefficient   Weighted scores   Multivariate analysis                                                     
  ------------------------------------------------------- ------------------------ --------------- ----------------- ------------------------------------------------ ------------------------ ---------
  RATD (cm)                                               5.249 (2.262, 12.389)    \<0.001         --                --                                               --                       --
  RALD (cm)                                               4.491 (2.138, 11.418)    \<0.001         --                --                                               --                       --
  RVEDTD (cm)                                             10.771 (4.311, 26.909)   \<0.001         1.665             2[†](#tfn4-copd-12-1741){ref-type="table-fn"}    5.283 (1.368, 20.403)    0.016
  RVEDLD (cm)                                             3.229 (1.426, 7.313)     0.005           --                --                                               --                       --
  PASP (mmHg)                                             23.688 (8.383, 66.940)   \<0.001         2.981             3[†](#tfn4-copd-12-1741){ref-type="table-fn"}    19.710 (5.032, 77.206)   \<0.001
  PAd (cm)                                                6.889 (2.789, 17.015)    \<0.001         1.941             2[†](#tfn4-copd-12-1741){ref-type="table-fn"}    6.963 (1.803, 26.893)    0.005
  ENDSEI                                                  16.593 (4.621, 59.581)   \<0.001         --                --                                               --                       --
  TAPSE (cm)                                              0.168 (0.058, 0.488)     0.001           −2.864            −3[†](#tfn4-copd-12-1741){ref-type="table-fn"}   0.057 (0.010, 0.320)     0.001

**Notes:**

Variables were transformed into binary variables according to optimum cutoff values.

If RVEDTD ≥3.8 cm or PAd ≥2.7 cm, weighted score =+2; if PASP ≥61 mmHg, weighted score =+3; and if TAPSE ≥1.65 cm, weighted score =−3.

**Abbreviations:** PH, pulmonary hypertension; RATD, right atrial transverse dimension; RALD, right atrial longitudinal dimension; RVEDTD, right ventricular end-diastolic transverse dimension; RVEDLD, right ventricular end-diastolic longitudinal dimension; PASP, pulmonary arterial systolic pressure; PAd, pulmonary artery diameter; ENDSEI, end-systolic-stage eccentricity index; TAPSE, tricuspid annular plane systolic excursion.

###### 

The distribution of echocardiography parameters and accuracy for discrimination

  Variable      All subjects (n=107)   Normal/PH (n=51)   Severe PH (n=56)   *P*-value   Sensitivity (%)   Specificity (%)   Area under the curve (95% CI)
  ------------- ---------------------- ------------------ ------------------ ----------- ----------------- ----------------- -------------------------------
  RATD (cm)                                                                                                                  
   \<4.2        46 (43.0)              33 (64.7)          13 (23.2)          \<0.001     0.768             0.647             0.707 (0.607, 0.807)
   ≥4.2         61 (57.0)              18 (35.3)          43 (76.8)                                                          
  RALD (cm)                                                                                                                  
   \<4.8        52 (48.6)              35 (68.6)          17 (30.4)          0.008       0.696             0.686             0.650 (0.543, 0.756)
   ≥4.8         55 (51.4)              16 (31.4)          39 (69.6)                                                          
  RVEDTD (cm)                                                                                                                
   \<3.8        47 (43.9)              14 (27.5)          10 (17.9)          \<0.001     0.821             0.725             0.801 (0.716, 0.886)
   ≥3.8         60 (56.1)              37 (72.5)          46 (82.1)                                                          
  RVEDLD (cm)                                                                                                                
   \<6.4        61 (57.0)              14 (27.5)          11 (19.6)          0.002       0.571             0.725             0.672 (0.569, 0.774)
   ≥6.4         46 (43.0)              37 (72.5)          45 (80.4)                                                          
  PASP (mmHg)                                                                                                                
   \<61         54 (50.5)              43 (84.3)          11 (19.6)          \<0.001     0.804             0.843             0.869 (0.797, 0.942)
   ≥61          53 (49.5)              8 (15.7)           45 (80.4)                                                          
  PAd (cm)                                                                                                                   
   \<2.7        57 (53.3)              39 (76.5)          18 (32.1)          \<0.001     0.679             0.765             0.745 (0.675, 0.855)
   ≥2.7         50 (46.7)              12 (23.5)          38 (67.9)                                                          
  ENDSEI                                                                                                                     
   \<1.05       48 (46.9)              35 (68.6)          13 (23.3)          \<0.001     0.768             0.683             0.792 (0.706, 0.878)
   ≥1.05        59 (55.1)              16 (31.4)          43 (76.8)                                                          
  TAPSE (cm)                                                                                                                 
   \<1.65       27 (25.2)              5 (9.8)            22 (39.3)          0.001       0.902             0.607             0.684 (0.584, 0.784)
   ≥1.65        80 (74.8)              46 (90.2)          34 (60.7)                                                          

**Note:** Data shown as n (%).

**Abbreviations:** PH, pulmonary hypertension; RATD, right atrial transverse dimension; RALD, right atrial longitudinal dimension; RVEDTD, right ventricular end-diastolic transverse dimension; RVEDLD, right ventricular end-diastolic longitudinal dimension; PASP, pulmonary arterial systolic pressure; PAd, pulmonary artery diameter; ENDSEI, end-systolic-stage eccentricity index; TAPSE, tricuspid annular plane systolic excursion.
